行情

PLSE

PLSE

脉冲生物科学
NASDAQ

实时行情|Nasdaq Last Sale

21.64
-0.06
-0.28%
休市 16:00 11/26 EST
开盘
21.09
昨收
21.70
最高
21.74
最低
21.07
成交量
2.91万
成交额
--
52周最高
45.82
52周最低
14.51
市值
6.41亿
市盈率(TTM)
-9.3360
分时
5日
1月
3月
1年
5年
Pulse Biosciences, Inc (PLSE)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks · 2天前
Pulse Biosciences 将参加 Stephens 年度投资会议
HAYWARD, Calif., November 18, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced plans to participate in the Stephens A...
Business Wire · 11/18 21:05
HC Wainwright & Co. Maintains Buy on Pulse Biosciences, Lowers Price Target to $43
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Pulse Biosciences (NASDAQ:PLSE) with a Buy and lowers the price target from $46 to $43.
Benzinga · 11/16 14:12
Pulse Biosciences Q3 EPS $(0.48) Beats $(0.53) Estimate, Sales $574.00K Beat $190.00K Estimate
Pulse Biosciences (NASDAQ:PLSE) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 5.88 percent increase over losses of $(0.51) per share from
Benzinga · 11/15 22:27
Pulse Biosciences 每股收益超过 0.05 美元,收入超过
Pulse Biosciences (NASDAQ:PLSE): Q3 GAAP EPS of -$0.48 beats by $0.05. Revenue of $574M beats by $573.81M. Press Release
Seekingalpha · 11/15 21:25
Pulse Biosciences to Present at the Stifel 2021 Virtual Healthcare Conference
HAYWARD, Calif., November 04, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company introducing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that members of management will present at...
Business Wire · 11/04 20:05
Pulse Biosciences 任命 Laureen DeBuono 为董事会成员
HAYWARD, Calif., October 05, 2021--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced the appointment of Laureen DeBuono to i...
Business Wire · 10/05 12:00
Brief-Pulse Biosciences 出售证券持有人可能要约或出售 300 万股
reuters.com · 09/03 21:31
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PLSE最新的财务预测,通过PLSE每股收益,每股净资产,每股现金流等数据分析脉冲生物科学近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

33.33%强力推荐
66.67%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PLSE价格均价为37.00,最高价位43.00,最低价为28.00。
最高43.00
均价37.00
最低28.00
现价21.64
EPS
实际EPS
预期EPS
-0.57-0.43-0.28-0.14
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 71
机构持股: 418.53万
持股比例: 14.12%
总股本: 2,963.13万
类型机构数股数
增持
19
81.61万
建仓
7
44.54万
减持
15
22.43万
平仓
5
7.51万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
先进医疗设备和技术
-0.02%
医疗设备和用品
-0.85%
高管信息
Non-Executive Chairman/Independent Director
Robert Duggan
President/Chief Executive Officer/Director
Darrin Uecker
Chief Financial Officer/Executive Vice President - Finance/Treasurer/Secretary
Sandra Gardiner
Executive Vice President/General Manager
Edward Ebbers
Director
Mitchell Levinson
Director
Shelley Spray
Independent Director
Manmeet Soni
Independent Director
Richard van den Broek
暂无数据
PLSE 简况
Pulse Biosciences, Inc.(原名: Electroblate, Inc. )是一家利用纳米脉冲电信号(NPES)平台技术的开发阶段的医疗器械公司。NPES是一种利用纳秒脉冲电场来诱导组织中细胞通路的细胞信号传导与激活的局部和非用药技术。NPES在一系列皮肤病学和美学应用中提供治疗。该公司为微创应用提供治疗,如心脏消融、肺部疾病、巴雷斯特食道症、甲状腺结节和耳鼻喉(ENT)乳头状瘤。 该公司正在开发一种实施NPES疗法的系统,被称为PulseTx系统(PulseTx)。PulseTx系统通过可调脉冲发生器及预先准备的电极套件提供NPES脉冲。PulseTx系统脉冲通过电极直接施加到组织,在细胞和细胞器膜中产生瞬时纳米孔。

微牛提供Pulse Biosciences Inc(NASDAQ-PLSE)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PLSE股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PLSE股票基本功能。